spacer
home > ebr > Winter 2010
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2010

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

   
Text
PDF
bullet
Business Development and Financing

Using case studies from major players in the pharmaceutical industry, Peter Thornton at Business Insights reviews strategies to revitalise R&D and boost flagging pipelines.

 
view
download pdf

Implementing a ‘roadbook-controlled project’ that takes into account the development process and financial and risk parameters can limit the waste of invested money through strategically placed ‘go/no go’ decision points, explains Roel Bellens at Strategus.

 
view
download pdf

John Nash, Alan Beresford and Dawn Yates at BioFocus argue that outsourcing ADME to CROs can eliminate potential development liabilities, cut costs by reducing time spent on unsuitable candidates, and provide access to a wide range of testing resources.

 
view
download pdf

There is currently global political and economic pressure to reduce the costs of healthcare. Michael F Swanick at PricewaterhouseCoopers examines the impact that rising tax rates will have on the biopharmaceutical industry over the next year.

 
view
download pdf

The European Commission released its final report on the Pharmaceutical Sector Inquiry in July this year, and it clearly aims to promote practices that increase the level of generic entries. Michael McFalls and Frances Murphy at Jones Day compare the report to US legislation and fear that it may lead to limitations that are a step too far.

 
view
download pdf

As companies expand globally, it is crucial that they maintain their efficiency and reputation through effective communication structures. Simone Lamont and Alison Lamb of CLS Communication AG point out the benefits of using the services of life science language specialists that fully understanding your business, ensuring seamless integration.

 
view
download pdf
bullet
BioResearch and Innovation

Matthew Sleeman and Fabio Magrini at MedImmune review developments in using antibodies to treat autoimmune diseases and in other areas of unmet medical need, and hope that this will continue to stimulate research into the pathogenic mechanisms of autoimmunity.

 
view
download pdf

Cervical cancer is the second most common cancer in women, and around 80 per cent of deaths resulting from it occur in developing countries. Julie Zhu at QIAGEN discusses how tools and technologies can be adapted for low-resource settings to ensure that women at risk can be identified worldwide.

 
view
download pdf
bullet
Discovery Technology

Technological advances have led to quantitative polymerase chain reaction (qPCR) becoming a quality validation method for a range of scientific and medical approaches. Tobias Hampshire at Thermo Fisher Scientific provides an overview of recent developments in probe-based technology.

 
view
download pdf

miRNAs are ideally suited for use as biomarkers due to their role in controlling cellular activity. By indicating the biological state of cells and tissues, Peer Staehler at febit argues that they are important to diagnostics and may have the potential to become therapeutic targets and tools.

 
view
download pdf
bullet
BioDevelopment and Regulatory

Andy Bailey at ViruSure GmbH reviews the latest regulations leading towards a new approach to virus safety for investigational biotechnology products.

 
view
download pdf

Quality assurance should be integral to clinical development and trials to ensure the accuracy of test results. Martin Crockard at Randox describes different types of analyses and explains that the choice of scheme should be dependent on the size, duration and complexity of the trial.

 
view
download pdf
bullet
BioFormulation and Manufacturing

William Downey at HighTech Business Decisions provides an overview of the results of an investigation into the criteria that directors of biomanufacturing companies believed to be most important when choosing a contract manufacturing organisation.

 
view
download pdf

The move towards personalised medicine has meant that a great number of samples are collected during clinical trials. In order to manage this data, a flexible information system that works in real-time should be employed, explains Jennifer Benner at BioStorage Technologies.

 
view
download pdf
bullet
BioRegional

Bob Smailes at LeidenUniversity outlines the research taking place at LeidenBioSciencePark, the leading life science park in the Netherlands.

 
view
download pdf

A new cGMP production centre is being built in Wallonia, allowing three companies who work in the field of regenerative medicines to come together to create one platform, where each will have their own production space and the support they need.

 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Arquer Diagnostics Appoints Nadia Whittley as CEO


More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

Industry Events

BioProcess International Conference & Exhibition (BPI)

25-28 September 2017, Hynes Convention Center, Boston, Massachusetts, USA

BioProcess International Conference & Exhibition (BPI) is the largest bioprocessing event bringing you the science, technologies and partners needed to accelerate promising biologics towards commercial success.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement